Chronic Spontaneous Urticaria Endotypes: Exploratory Proteomic Analysis in the Benralizumab ARROYO Study
Summary In this post hoc analysis funded by AstraZeneca, benralizumab reduced eosinophil‐related protein biomarker expression. Benralizumab reduced eosinophil‐derived neurotoxin concentrations, which were dose‐independent and irrespective of BHRA status.
Authors
- Mathias Cardner (ORCID: https://orcid.org/0000-0001-5873-2632)
- Daniel Muthas (ORCID: https://orcid.org/0000-0001-9320-2004)
- Eva Rodríguez‐Suárez
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- Adam Platt (ORCID: https://orcid.org/0009-0008-0109-7699)
- Sabine Altrichter (ORCID: https://orcid.org/0000-0001-9955-385X)
- Christopher McCrae (ORCID: https://orcid.org/0000-0001-7184-9069)
- Martin Metz (ORCID: https://orcid.org/0000-0002-4070-9976)
- Lisa A. Beck (ORCID: https://orcid.org/0000-0002-8452-667X)
- Jonathan A. Bernstein (ORCID: https://orcid.org/0000-0002-3476-1196)
- Chris Chamberlain
Institutions
- Johannes Kepler University of Linz (AT)
- Universitat Pompeu Fabra (ES)
- University of Rochester Medical Center (US)
- Humboldt-Universität zu Berlin (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Bernstein Clinical Research Center (US)
- Kepler Universitätsklinikum (AT)
- AstraZeneca (Finland) (FI)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-10-06
- DOI
- https://doi.org/10.1111/cea.70434
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00